Aspirin for Prevention of Preeclampsia

Overview

Prophylaxis with low-dose aspirin has been recommended to prevent preeclampsia, the rationale being that hypertension and abnormalities of coagulation in this disease are caused in part by an imbalance between vasodilating and vasoconstricting prostaglandins. Low-dose aspirin therapy inhibits thromboxane production more than prostacyclin production and therefore should protect against vasoconstriction and pathologic blood coagulation in the placenta. Initially, several single-center trials, mostly among women at increased risk for preeclampsia, demonstrated a substantial reduction in the risk of proteinuric hypertension as well as reductions in the incidences of preterm birth, infants small for gestational age, and perinatal death,

Full Title of Study: “Comparison of Two Doses (81 mg Versus 162mg) of Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women: A Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 30, 2020

Detailed Description

This will be a randomized control trial to estimate the efficacy of two doses (80 mg versus 160 mg) of aspirin for prevention of preeclampsia in High-Risk Pregnant Women identified in the first trimester to be at high risk.

Interventions

  • Drug: aspirin 162 mg
    • Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
  • Drug: aspirin 81 mg
    • Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
  • Drug: placebo
    • placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first

Arms, Groups and Cohorts

  • Active Comparator: aspirin 162 mg
    • Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
  • Active Comparator: aspirin 81 mg plus placebo
    • Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With early Preeclampsia
    • Time Frame: 6 months
    • The number of cases of preeclampsia that appear in both groups before 34 weeks of pregnancy.Blood pressure greater than 140/90 on 2 occasions 6 hrs apart and significant proteinuria (greater than 300 mg in 24 hrs) before 34 weeks gestation

Secondary Measures

  • Prevention of preeclampsia between 37 and 41
    • Time Frame: 6 months
    • The number of cases of preeclampsia that appear in both groups between 37 and 41 weeks of pregnancy.
  • The number of cases of Fetal Growth Restriction
    • Time Frame: 6 months
    • The number of cases of fetal growth restriction, defined as a fetal weight below the 10th percentile and an abnormal umbilical cord doppler that appear in both groups at any given time during pregnancy.
  • The number of cases of preterm birth
    • Time Frame: 6 months
    • The number of cases delivered before 37 weeks gestation

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant women presenting prior to 17+0 weeks' gestation. – Moderate to high risk of preeclampsia. – One or more of the following: previous history of preeclampsia, antiphospholipid antibodies, pre-existing diabetes, pre-existing hypertension, pre-existing renal disease, autoimmune disease, nulliparity, family history of preeclampsia, elevated BMI > 25, and maternal age <20 or >35. – Give written informed consent. Exclusion Criteria:

  • Multiple gestations, – fetal aneuploidy – major fetal structural anomaly – bleeding disorder – allergy to aspirin – women already on aspirin or heparin.

Gender Eligibility: Female

The population of interest involves women attending the study hospital for antenatal care and delivery

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Aswan University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: hany farouk, Principal Investigator – Aswan University Hospital
  • Overall Official(s)
    • hany f sallam, md, Principal Investigator, Aswan University Hospital
  • Overall Contact(s)
    • hany f sallam, md, 01022336052, hany.farouk@aswu.edu.eg

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.